

**REMARKS**

***Claim Amendments***

Upon entry of the foregoing amendment, claims 16, 19-20, 26-31, 37-46, 49, and 50 are pending in the application. Please cancel claims 32-33 and 47-48 without prejudice or disclaimer to the subject matter therein. Please amend claims 16, 19-20, 28-31, 38-41, and 44-46. Please add new claim 50. Support for the amendments can be found throughout the specification and in the claims as originally filed and, in particular, at ¶¶ 2, 14, 21-23, 43-44, and 69. Applicants respectfully request entry of the above amendment and submit that the above amendment does not constitute new matter.

***35 U.S.C. § 112, First Paragraph (Enablement)***

Claims 16-37 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement.

Applicants have amended independent claims 16, 19, 20, 39, and 40 to recite “Cofilin comprising the amino acid sequence of SEQ ID NO: 1.” Applicants believe this amendment renders this rejection *moot*. *See e.g.*, Advisory Action mailed on October 27, 2006 at page 2. To the extent that the rejection applies to the claims as amended, Applicants respectfully request consideration of Applicants’ arguments filed on September 7, 2006.

In view of the foregoing, Applicants respectfully request withdrawal of the 35 U.S.C. § 112, 1<sup>st</sup> paragraph (enablement) rejection.

***35 U.S.C. § 112, First Paragraph (Written Description)***

Claims 16-35 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement.

As discussed above, Applicants have amended the independent claims. Applicants believe this amendment renders this rejection *moot*. *See e.g.*, Advisory Action mailed on October 27, 2006 at page 2. To the extent that the rejection applies to the claims as amended, Applicants respectfully request consideration of Applicants’ arguments filed on September 7, 2006.

In view of the foregoing, Applicants respectfully request withdrawal of the 35 U.S.C. § 112, 1<sup>st</sup> paragraph (written description) rejection.

***35 U.S.C. § 112, Second Paragraph***

Claims 20 and 34 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly being indefinite.

Applicants have deleted the recitation of “regenerative medicine.” Applicants believe this amendment renders the rejection *moot*. *See e.g.*, Advisory Action mailed on October 27, 2006 at page 2.


**CONCLUSION**

Applicants respectfully submit that claims are in condition for allowance, and such disposition is earnestly solicited. Should the Examiner believe that any issues remain after consideration of this response, the Examiner is invited to contact the Applicants' undersigned representatives to discuss and resolve such issues.

In the event that a variance exists between the amount tendered and that deemed necessary by the U.S. Patent and Trademark Office to enter and consider this response or to maintain the present application pending, please credit or charge such variance to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,  
HUNTON & WILLIAMS LLP

Dated: April 9, 2007

By:   
Robert M. Schulman  
Registration No. 31,196

Alexander H. Spiegler  
Registration No. 56,625

HUNTON & WILLIAMS LLP  
Litigation & Intellectual Property  
1900 K Street, N.W. Suite 1200  
Washington, D.C. 20006-1109  
Telephone: (202) 955-1500  
Facsimile: (202) 778-2201

RMS/AHS:itm